A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) Versus Vehicle Gel
Phase of Trial: Phase III
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Loteprednol etabonate (Primary)
- Indications Ocular inflammation; Ocular pain
- Focus Therapeutic Use
- Sponsors Valeant Pharmaceuticals International
- 25 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
- 25 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 15 May 2017.
- 24 Jan 2017 Status changed from not yet recruiting to recruiting.